Tofacitinib in the Management of Alopecia Universalis

This case report documents the successful use of tofacitinib, a Janus kinase (JAK) inhibitor, in treating a 37-year-old female patient with alopecia universalis (AU). The patient experienced significant hair regrowth on the scalp and eyebrows after 6 months of treatment with tofacitinib 5 mg twice daily, along with oral mini-pulse betamethasone, topical minoxidil 5%, and clobetasol lotion. The treatment was well-tolerated with no notable adverse effects. This case supports the potential efficacy and safety of tofacitinib in managing AU, though larger-scale studies and long-term follow-up are needed to confirm these findings and optimize treatment protocols.